Rebalix
Logo LGIMLGIM · sheet of 10 September 2026
ETF sheet · official issuer and register data

L&G S&P 100 Equal Weight UCITS ETF

SP1E · IE000YELA4E3 · class USD Acc. · USD · domicile Ireland
Equity · United States · Large cap · Risk paritySFDR art. 6 (inferred)
Index tracked: S&P 100 Equal Weight Index Net Total Return
TER
0.19%+ trans. 0.02%
Fund size
30 m EUR
Tracking difference
not computable
🇮🇹 tax rate
white list not published
Replication
Physical (full replication)
Income
Accumulating
Launch 17 Jul 2025 · costs from the KID as of 2 Sept 2026 · 0 securities held · 9 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 4 Aug 2026
The investment objective of the Fund is to provide equally weighted exposure to the large cap equity market in the United States. The Fund is passively managed and aims to track the performance of the S&P 100 Equal Weight Index Net Total Return (the “Index”), before the deduction of fees and expenses. The Index is designed to provide equally weighted exposure to large capitalisation equity securities listed in the United States, in accordance with its methodology. The Fund seeks to achieve its investment objective by investing primarily in equity…

Performance since series start (in euro) — base 100

15 Jul 202531 Jul 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
2026124100122
High 124 (28 Jul 2026) · low 100 (7 Aug 2025) · last 122. Past performance is not indicative of future results.

Returns in euro

1 year+19.6%
3 yearsseries too young
5 yearsseries too young
10 yearsseries too young
Since series start+22.0%

Risk · 1 / 3 / 5 years

Volatility (ann.)10.71%10.71%
Max drawdown−7.71%−7.71%
Sharpe1.541.54
Sortino2.292.29
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · SP1E · IE000YELA4E31
RebalixSP1E · IE000YELA4E3 · sheet of 10 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years
Not honestly computable: index series not published by the issuer

Holdings

Portfolio as declared by the issuer · 30 Jun 2026 · 0 securities · top-10 weight = 11.4%
Top holdingsWeight
RTX1.2%
Booking Holdings Inc1.2%
Thermo Fisher Scientific1.2%
Abbott Laboratories1.2%
Charles Schwab Corp1.1%
Capital One1.1%
Bristol-myers Squibb1.1%
Mastercard1.1%
Microsoft1.1%
Ge Vernova Inc1.1%
Countries (% of fund)
Stati Uniti100.0%
Sectors (% of fund)
Informatica18.9%Finanziari16.0%Industriali15.6%Assistenza sanitaria15.6%Beni di consumo voluttuari9.0%

Listing venues

ESMA register (FIRDS) and official exchange lists
SP1E · Borsa Italiana (ETFplus)
SNPE · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 5 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · fundcentres.landg.com/srp/documents-id/f761afaa-1940-4f9d-a5df-bd0e173
Factsheet · fundcentres.landg.com/srp/documents-id/d2f82ec4-0693-4225-ab84-41ddfc9
Prospectus · fundcentres.landg.com/srp/lit/7qeQjP/Prospectus_Legal-General-UCITS-ET
The live sheet, always up to date
rebalix.com/en/etf/IE000YELA4E3
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · SP1E · IE000YELA4E32